ClinicalTrials.gg
RecruitingNCT06785272MAGICIANUpdated Dec 18, 2025

Magnesium Trial in Acute Asthma in Emergency Department

A Phase 3 interventional study of magnesium sulfate and Normal Saline in Asthma, sponsored by Suzanne Schuh. Recruiting at 6 sites in Canada. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Suzanne Schuh · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing Magnesium Sulfate in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. Magnesium Sulfate · Asthma.

Planned enrollment
3rd of 13
192 · median 90
Started
2025
with 1 other
Phase 3
3 of 13
2 open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Suzanne Schuh

Among the 13 studies testing Magnesium Sulfate in Asthma, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 12th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 13 studies testing Magnesium Sulfate in Asthma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Magnesium Sulfate

Magnesium Sulfate: first FDA approval 1981 (TIS-U-SOL IN PLASTIC CONTAINER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing Magnesium Sulfate in Asthma, or all of them as a file.
02

Study summary

Despite optimal initial emergency department (ED) therapy, 50% of children with severe acute asthma have ongoing moderate-severe respiratory distress. Guidelines recommend intravenous magnesium (IVMg) for them, yet evidence for IVMg efficacy is scant and disparate. While early small Randomized Controlled Trials (RCTs) suggested hospitalization benefit, recent large observational studies found no association between IVMg and improved outcomes. IVMg therapy is resource-intensive, can cause hypotension and demands close monitoring. Previous RCTs only assessed early Mg effect at 1-2 hours, overlooked the peak effect of key co-interventions such as corticosteroids and did not use validated scores. IVMg use is variable and often delayed until ≥4 hours after ED therapy is started and after the hospitalization decision has been made. Thus, in observational studies children given IVMg are 6-10 times more likely to be hospitalized; these studies have major confounding and the true IVMg treatment effect is thus unknown. To conclusively determine if IVMg alters the exacerbation course, it must be given early, and the primary outcome measure should be the severity of respiratory distress measured at the peak effect of key co-interventions to focus on a clinically meaningful and objective effect. The Pediatric Respiratory Assessment Measure (PRAM)-a valid, discriminative, reproducible and responsive-to-change instrument-is thus the ideal primary outcome measure. Hospitalization outcome has major confounding by indication and MD perceptions.

Primary Aim: In children with acute asthma remaining in moderate-severe distress after 1 hour of initial ED therapy, is early IVMg therapy associated with a significantly greater improvement in respiratory distress, measured by PRAM, at 2 hours after starting the intervention, compared to placebo? Hypothesis: IVMg will yield significantly greater PRAM improvement of ≥1.0 point than placebo.

Expected Outcomes: This trial will clarify if there is an incremental benefit of IVMg in decreasing respiratory distress in pediatric refractory acute asthma. A positive result will establish a proven standard of care for this indication, with a need for Knowledge Translation (KT) to implement routine early IVMg therapy. A negative result will lead to de-implementation of IVMg which may also lead to cost savings.

Read the detailed description

The investigators propose a 6-centre randomized, double-blind, placebo-controlled trial. Two groups will be compared: IV Mg sulfate and IV (intravenous) 0.9% saline placebo. After initial therapy with the systemic Corticosteroids (CSs) routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium (ipratropium use as per local practice), eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate (maximum 2.0 g) [experimental group] or an identical volume of 0.9% saline [control group]. Outcomes will be measured during the 180-minute observational period in the ED and at 72 hours post ED discharge.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma, magnesium sulfate
  • pediatric, acute asthma
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 2.00-17.99 years (prior to 18th birthday),
  2. Diagnosis of asthma, defined as an asthma or probable asthma diagnosis/asthma-like phenotype made by a physician (this includes ED physician) in a patient who in the opinion of the treating ED physician requires therapy for acute asthma in the ED (GINA asthma guidelines, 2024).
  3. Moderate-severe asthma after initial therapy with 3 treatments of inhaled salbutamol and ipratropium, defined as an eligibility PRAM ≥5, indicating a strong association with hospitalization.

Exclusion criteria

Exclusion criteria:

  1. Receipt of IVMg within 24 hours prior to ED arrival.
  2. Need for airway support on arrival. (Airway support on arrival meeting exclusion criteria will include immediate need for high flow nasal cannula therapy, non-invasive CPAP/bi-PAP ventilation or invasive ventilation with endotracheal intubation, as decided by the attending Emergency Department (ED) physician. Supplemental oxygen therapy will not represent an exclusion criterion.)
  3. Known renal, chronic pulmonary, neurologic, cardiac or systemic disease: these may influence outcomes after Mg.
  4. Known to Mg sulfate.
  5. Previous enrollment.
  6. Poor mastery of English and/or French language precluding understanding.
  7. No phone/email; unavailable for follow-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    This group will receive a single dose of intravenous magnesium sulfate over 30 minutes. After this treatment has been completed, they may also get further Ventolin inhalations or other asthma medicines which are not part of the study, as recommended by the emergency physician. The participant will be monitored closely by the study nurse who will measure their breathing, heart rate, blood pressure and oxygen for 3 hours after the study treatment. The study nurse will also notify the emergency physician of any major changes.

    Drug: magnesium sulfate

  • Placebo comparator
    Placebo Group

    This group, will receive a single dose of intravenous placebo (normal saline, i.e. salt water) over 30 minutes. After this treatment has been completed, they may also get further Ventolin inhalations or other asthma medicines which are not part of the study, as recommended by the emergency physician who is taking care of the participant. They will be monitored closely by the study nurse who will measure the participant's breathing, heart rate, blood pressure and oxygen for 3 hours after the study treatment. The study nurse will also notify the emergency physician of any major changes in their health.

    Drug: Normal Saline

Interventions

  • After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]

  • DrugNormal Saline

    After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].

06

What researchers measure

Primary outcomes

  1. Pediatric Respiratory Assessment Measure (PRAM) score: This score ranges from 0-12. A score from 0-3 is mild, 4-7 moderate and 8-12 severe. A low score is a better outcome and a high score is a worse outcome.

    PRAM is a validated 12-point asthma severity score which exhibits the most comprehensive measurement properties of all asthma scores and has been successfully used as an outcome in major trials. It is the only score with demonstrated criterion validity, using respiratory resistance as the gold standard. PRAM has been validated in both preschool and school-aged children in the ED with asthma and has strong association with admission. PRAM has inter-rater reliability above 70% and is adopted in all pediatric EDs in Canada. Most children treated for acute asthma are preschoolers who lack coordination to perform pulmonary function tests reliably. To maximize the accuracy of the PRAM measurement, all study nurses will complete an online PRAM training module. We will use an eligibility cut-off of PRAM ≥ 5 post initial therapy as this is associated with clinically concerning respiratory distress requiring further intervention. A PRAM score from 0-3 is mild, 4-7 moderate and 8-12 severe.

    Time frame: The primary outcome measure will be the PRAM score at 120 minutes post start of experimental therapy.

Secondary outcomes

  1. Changes in PRAM score

    Changes in vital signs

    Time frame: Changes in PRAM score from baseline (pre intervention) to 30, 60, 120, 180 minutes after start of experimental therapy

  2. Hospitalization for asthma at the index ED visit

    Defined as admission to an inpatient unit due to continued/worsening distress

    Time frame: Up to 24 hours after starting experimental therapy

  3. Changes in respiratory rate

    Changes in vital signs

    Time frame: From baseline (pre-intervention) to 30,60,120 and 180 minutes post intervention (respiratory rate )

  4. Changes in oxygen saturation

    Changes in vital signs

    Time frame: From baseline (pre-intervention) to 30,60,120 and 180 minutes post intervention ( oxygen saturation)

  5. Changes in blood pressure

    Changes in vital signs

    Time frame: From baseline (pre-intervention) to 10,20,30,60,120, and 180 minutes post intervention (blood pressure).

  6. PRAM denoting mild asthma (≤ 3 points is a widely accepted discharge criterion).

    Pediatric Respiratory Assessment Measure (PRAM) is a valid clinical score assessing acute asthma severity in toddlers and teenages. Score ranges from 0 to 12 (mild to severe). A higher score is a more severe asthma measurement. A low score is a better outcome than a high score.

    Time frame: at 120 minutes post intervention

  7. Hospitalization for asthma at any medical facility

    Defined as admission to an inpatient unit due to continued/worsening distress

    Time frame: within 72 hours post- ED discharge

  8. Unscheduled asthma-related visits to any health care provider

    Family-initiated asthma-related medical visit

    Time frame: within 72 hours post- ED discharge

  9. Hospital length of stay.

    Length of stay is the duration of a hospital stay in hours

    Time frame: From presentation at the Emergency Department triage to the time of hospital discharge, up to 4 weeks.

07

Study locations

1 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 32 non-industry phase 3 interventional studies under Asthma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 24 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 21, 2025
StartActual
Oct 8, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06785272
Lead sponsor
Suzanne Schuh
Collaborators
Alberta Children's Hospital, McMaster Children's Hospital, Stollery Children's Hospital, Children's Hospital of Eastern Ontario, St. Justine's Hospital, The Hospital for Sick Children
Responsible party
Suzanne Schuh (Staff Physician, The Hospital for Sick Children) — Sponsor-investigator
First posted
Jan 21, 2025
Start date
Oct 8, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Dec 18, 2025

Study contacts

Sunita O'Shea
Contact
sunita.oshea@sickkids.ca
416-813-7654 ext. 228453
Yaron Finkelstein, MD
Contact
yaron.finkelstein@sickkids.ca
416-813-7654 ext. 405317
Suzanne Schuh, MD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magnesium Sulfate

Start the discussion